Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …

BCL2 and MCL1 are commonly expressed prosurvival (antiapoptotic) proteins in
hematologic cancers and play important roles in their biology either through dysregulation or …

METHODS Previously untreated CLL patients age< 70 years received three cycles of
ibrutinib and then 12 cycles of combined ibrutinib plus venetoclax. Patients in the MRD …

With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …

Background GLOW is a phase 3 trial evaluating the efficacy and safety of ibrutinib-
venetoclax in older patients and/or those with comorbidities with previously untreated …

Data on long-term outcomes and biological drivers associated with depth of remission after
BCL2 inhibition by venetoclax in the treatment of chronic lymphocytic leukemia (CLL) are …

PURPOSE The CLL14 study has established one-year fixed-duration treatment of
venetoclax and obinutuzumab (Ven-Obi) for patients with previously untreated chronic …

The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton's tyrosine …

Abstract iLLUMINATE is a randomized, open-label phase III study of ibrutinib plus
obinutuzumab (n= 113) versus chlorambucil plus obinutuzumab (n= 116) as first-line …

Background We hypothesised that combining zanubrutinib with obinutuzumab and
venetoclax (BOVen) as an initial therapy for chronic lymphocytic leukaemia and small …